Outcome and Predictive Factors in Uterine Carcinosarcoma Using Postoperative Radiotherapy: A Rare Cancer Network Study
Identifieur interne : 000634 ( Pmc/Curation ); précédent : 000633; suivant : 000635Outcome and Predictive Factors in Uterine Carcinosarcoma Using Postoperative Radiotherapy: A Rare Cancer Network Study
Auteurs : Daniel R. Zwahlen [Suisse, Australie] ; Ulrike Schick ; Yasemin Bolukbasi [Turquie] ; Juliette Thariat [France] ; Roxolyana Abdah-Bortnyak [Israël] ; Abraham Kuten [Israël] ; Sefik Igdem [Turquie] ; Hale Caglar [Turquie] ; Zeynep Ozsaran [Turquie] ; Kristina Loessl [Suisse] ; Kaouthar Khanfir Belkaaloul [Suisse] ; Sylviane Villette [France] ; Hansjörg VeesSource :
- Rare Tumors [ 2036-3605 ] ; 2016.
Abstract
Uterine carcinosarcomas (UCS) are rare tumors. Consensus regarding therapeutic management in non-metastatic disease is lacking. This study reports on outcome and predictive factors when using postoperative radiotherapy. We analyzed a retrospective analysis in 124 women treated between 1987-2007 in the framework of the Rare-Cancer-Network. Median follow-up was 27 months. Postoperative pelvic EBRT was administered in 105 women (85%) and 92 patients (74%) received exclusive or additional vaginal brachytherapy. Five-year overall survival (OS), disease-free survival (DFS), cancer specific survival (CSS) and locoregional control (LRC) were 51.6% (95% CI 35-73%), 53.7% (39-71%), 58.6% (38-74%) and 48% (38-67%). Multivariate analysis showed that external beam radiation therapy (EBRT) >50Gy was an independent prognostic factor for better OS (P=0.03), CSS (P=0.02) and LRC (P=0.01). Relative risks (RR) for better OS (P=0.02), DFS (P=0.04) and LRC (P=0.01) were significantly associated with younger age (≤60 years). Higher brachytherapy (BT)-dose (>9Gy) improved DFS (P=0.04) and LRC (P=0.008). We concluded that UCS has high systemic failure rate. Local relapse was reduced by a relative risk factor of over three in all stages of diseases when using higher doses for EBRT and brachytherapy. Postoperative RT was most effective in UCS stage I/II-diseases.
Url:
DOI: 10.4081/rt.2016.6052
PubMed: 27441069
PubMed Central: 4935818
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000635
Links to Exploration step
PMC:4935818Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Outcome and Predictive Factors in Uterine Carcinosarcoma Using Postoperative Radiotherapy: A Rare Cancer Network Study</title><author><name sortKey="Zwahlen, Daniel R" sort="Zwahlen, Daniel R" uniqKey="Zwahlen D" first="Daniel R." last="Zwahlen">Daniel R. Zwahlen</name><affiliation wicri:level="1"><nlm:aff id="aff001">Department of Radiation Oncology,<institution>Kantonsspital Graubuenden</institution>,<addr-line>Chur, Switzerland</addr-line></nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Chur</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="aff002">Department of Radiation Oncology,<institution>William Buckland Radiotherapy Centre, Alfred Health</institution>,<addr-line>Melbourne, Australia</addr-line></nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea>Melbourne</wicri:regionArea></affiliation></author><author><name sortKey="Schick, Ulrike" sort="Schick, Ulrike" uniqKey="Schick U" first="Ulrike" last="Schick">Ulrike Schick</name><affiliation><nlm:aff id="aff003">Department of Radiation Oncology,<institution>University Hospital Geneva</institution>,<addr-line>Switzerland</addr-line></nlm:aff></affiliation></author><author><name sortKey="Bolukbasi, Yasemin" sort="Bolukbasi, Yasemin" uniqKey="Bolukbasi Y" first="Yasemin" last="Bolukbasi">Yasemin Bolukbasi</name><affiliation wicri:level="1"><nlm:aff id="aff004">Department of Radiation Oncology,<institution>Ege University Hospital</institution>,<addr-line>Izmir, Turkey</addr-line></nlm:aff><country xml:lang="fr">Turquie</country><wicri:regionArea>Izmir</wicri:regionArea></affiliation></author><author><name sortKey="Thariat, Juliette" sort="Thariat, Juliette" uniqKey="Thariat J" first="Juliette" last="Thariat">Juliette Thariat</name><affiliation wicri:level="1"><nlm:aff id="aff005">Department of Radiation Oncology,<institution>Antoine Lacassagne Center</institution>,<addr-line>Nice, France</addr-line></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Nice</wicri:regionArea></affiliation></author><author><name sortKey="Abdah Bortnyak, Roxolyana" sort="Abdah Bortnyak, Roxolyana" uniqKey="Abdah Bortnyak R" first="Roxolyana" last="Abdah-Bortnyak">Roxolyana Abdah-Bortnyak</name><affiliation wicri:level="1"><nlm:aff id="aff006">Department of Radiation Oncology,<institution>Rambam Medical Center</institution>,<addr-line>Haifa, Israel</addr-line></nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Haifa</wicri:regionArea></affiliation></author><author><name sortKey="Kuten, Abraham" sort="Kuten, Abraham" uniqKey="Kuten A" first="Abraham" last="Kuten">Abraham Kuten</name><affiliation wicri:level="1"><nlm:aff id="aff006">Department of Radiation Oncology,<institution>Rambam Medical Center</institution>,<addr-line>Haifa, Israel</addr-line></nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Haifa</wicri:regionArea></affiliation></author><author><name sortKey="Igdem, Sefik" sort="Igdem, Sefik" uniqKey="Igdem S" first="Sefik" last="Igdem">Sefik Igdem</name><affiliation wicri:level="1"><nlm:aff id="aff007">Department of Radiation Oncology,<institution>Metropolitan Hospital</institution>,<addr-line>Istanbul, Turkey</addr-line></nlm:aff><country xml:lang="fr">Turquie</country><wicri:regionArea>Istanbul</wicri:regionArea></affiliation></author><author><name sortKey="Caglar, Hale" sort="Caglar, Hale" uniqKey="Caglar H" first="Hale" last="Caglar">Hale Caglar</name><affiliation wicri:level="1"><nlm:aff id="aff008">Department of Radiation Oncology,<institution>Marmara University Hospital</institution>,<addr-line>Istanbul, Turkey</addr-line></nlm:aff><country xml:lang="fr">Turquie</country><wicri:regionArea>Istanbul</wicri:regionArea></affiliation></author><author><name sortKey="Ozsaran, Zeynep" sort="Ozsaran, Zeynep" uniqKey="Ozsaran Z" first="Zeynep" last="Ozsaran">Zeynep Ozsaran</name><affiliation wicri:level="1"><nlm:aff id="aff004">Department of Radiation Oncology,<institution>Ege University Hospital</institution>,<addr-line>Izmir, Turkey</addr-line></nlm:aff><country xml:lang="fr">Turquie</country><wicri:regionArea>Izmir</wicri:regionArea></affiliation></author><author><name sortKey="Loessl, Kristina" sort="Loessl, Kristina" uniqKey="Loessl K" first="Kristina" last="Loessl">Kristina Loessl</name><affiliation wicri:level="1"><nlm:aff id="aff009">Department of Radiation Oncology,<institution>University Hospital</institution>,<addr-line>Bern, Switzerland</addr-line></nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Bern</wicri:regionArea></affiliation></author><author><name sortKey="Belkaaloul, Kaouthar Khanfir" sort="Belkaaloul, Kaouthar Khanfir" uniqKey="Belkaaloul K" first="Kaouthar Khanfir" last="Belkaaloul">Kaouthar Khanfir Belkaaloul</name><affiliation wicri:level="1"><nlm:aff id="aff010">Department of Radiation Oncology,<institution>Hôpital du Valais</institution>,<addr-line>Sion, Switzerland</addr-line></nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Sion</wicri:regionArea></affiliation></author><author><name sortKey="Villette, Sylviane" sort="Villette, Sylviane" uniqKey="Villette S" first="Sylviane" last="Villette">Sylviane Villette</name><affiliation wicri:level="1"><nlm:aff id="aff011">Department of Radiation Oncology,<institution>René Huguenin Center</institution>,<addr-line>Saint-Cloud, France</addr-line></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Saint-Cloud</wicri:regionArea></affiliation></author><author><name sortKey="Vees, Hansjorg" sort="Vees, Hansjorg" uniqKey="Vees H" first="Hansjörg" last="Vees">Hansjörg Vees</name><affiliation><nlm:aff id="aff003">Department of Radiation Oncology,<institution>University Hospital Geneva</institution>,<addr-line>Switzerland</addr-line></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">27441069</idno><idno type="pmc">4935818</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4935818</idno><idno type="RBID">PMC:4935818</idno><idno type="doi">10.4081/rt.2016.6052</idno><date when="2016">2016</date><idno type="wicri:Area/Pmc/Corpus">000635</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000635</idno><idno type="wicri:Area/Pmc/Curation">000634</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000634</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Outcome and Predictive Factors in Uterine Carcinosarcoma Using Postoperative Radiotherapy: A Rare Cancer Network Study</title><author><name sortKey="Zwahlen, Daniel R" sort="Zwahlen, Daniel R" uniqKey="Zwahlen D" first="Daniel R." last="Zwahlen">Daniel R. Zwahlen</name><affiliation wicri:level="1"><nlm:aff id="aff001">Department of Radiation Oncology,<institution>Kantonsspital Graubuenden</institution>,<addr-line>Chur, Switzerland</addr-line></nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Chur</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="aff002">Department of Radiation Oncology,<institution>William Buckland Radiotherapy Centre, Alfred Health</institution>,<addr-line>Melbourne, Australia</addr-line></nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea>Melbourne</wicri:regionArea></affiliation></author><author><name sortKey="Schick, Ulrike" sort="Schick, Ulrike" uniqKey="Schick U" first="Ulrike" last="Schick">Ulrike Schick</name><affiliation><nlm:aff id="aff003">Department of Radiation Oncology,<institution>University Hospital Geneva</institution>,<addr-line>Switzerland</addr-line></nlm:aff></affiliation></author><author><name sortKey="Bolukbasi, Yasemin" sort="Bolukbasi, Yasemin" uniqKey="Bolukbasi Y" first="Yasemin" last="Bolukbasi">Yasemin Bolukbasi</name><affiliation wicri:level="1"><nlm:aff id="aff004">Department of Radiation Oncology,<institution>Ege University Hospital</institution>,<addr-line>Izmir, Turkey</addr-line></nlm:aff><country xml:lang="fr">Turquie</country><wicri:regionArea>Izmir</wicri:regionArea></affiliation></author><author><name sortKey="Thariat, Juliette" sort="Thariat, Juliette" uniqKey="Thariat J" first="Juliette" last="Thariat">Juliette Thariat</name><affiliation wicri:level="1"><nlm:aff id="aff005">Department of Radiation Oncology,<institution>Antoine Lacassagne Center</institution>,<addr-line>Nice, France</addr-line></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Nice</wicri:regionArea></affiliation></author><author><name sortKey="Abdah Bortnyak, Roxolyana" sort="Abdah Bortnyak, Roxolyana" uniqKey="Abdah Bortnyak R" first="Roxolyana" last="Abdah-Bortnyak">Roxolyana Abdah-Bortnyak</name><affiliation wicri:level="1"><nlm:aff id="aff006">Department of Radiation Oncology,<institution>Rambam Medical Center</institution>,<addr-line>Haifa, Israel</addr-line></nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Haifa</wicri:regionArea></affiliation></author><author><name sortKey="Kuten, Abraham" sort="Kuten, Abraham" uniqKey="Kuten A" first="Abraham" last="Kuten">Abraham Kuten</name><affiliation wicri:level="1"><nlm:aff id="aff006">Department of Radiation Oncology,<institution>Rambam Medical Center</institution>,<addr-line>Haifa, Israel</addr-line></nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea>Haifa</wicri:regionArea></affiliation></author><author><name sortKey="Igdem, Sefik" sort="Igdem, Sefik" uniqKey="Igdem S" first="Sefik" last="Igdem">Sefik Igdem</name><affiliation wicri:level="1"><nlm:aff id="aff007">Department of Radiation Oncology,<institution>Metropolitan Hospital</institution>,<addr-line>Istanbul, Turkey</addr-line></nlm:aff><country xml:lang="fr">Turquie</country><wicri:regionArea>Istanbul</wicri:regionArea></affiliation></author><author><name sortKey="Caglar, Hale" sort="Caglar, Hale" uniqKey="Caglar H" first="Hale" last="Caglar">Hale Caglar</name><affiliation wicri:level="1"><nlm:aff id="aff008">Department of Radiation Oncology,<institution>Marmara University Hospital</institution>,<addr-line>Istanbul, Turkey</addr-line></nlm:aff><country xml:lang="fr">Turquie</country><wicri:regionArea>Istanbul</wicri:regionArea></affiliation></author><author><name sortKey="Ozsaran, Zeynep" sort="Ozsaran, Zeynep" uniqKey="Ozsaran Z" first="Zeynep" last="Ozsaran">Zeynep Ozsaran</name><affiliation wicri:level="1"><nlm:aff id="aff004">Department of Radiation Oncology,<institution>Ege University Hospital</institution>,<addr-line>Izmir, Turkey</addr-line></nlm:aff><country xml:lang="fr">Turquie</country><wicri:regionArea>Izmir</wicri:regionArea></affiliation></author><author><name sortKey="Loessl, Kristina" sort="Loessl, Kristina" uniqKey="Loessl K" first="Kristina" last="Loessl">Kristina Loessl</name><affiliation wicri:level="1"><nlm:aff id="aff009">Department of Radiation Oncology,<institution>University Hospital</institution>,<addr-line>Bern, Switzerland</addr-line></nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Bern</wicri:regionArea></affiliation></author><author><name sortKey="Belkaaloul, Kaouthar Khanfir" sort="Belkaaloul, Kaouthar Khanfir" uniqKey="Belkaaloul K" first="Kaouthar Khanfir" last="Belkaaloul">Kaouthar Khanfir Belkaaloul</name><affiliation wicri:level="1"><nlm:aff id="aff010">Department of Radiation Oncology,<institution>Hôpital du Valais</institution>,<addr-line>Sion, Switzerland</addr-line></nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Sion</wicri:regionArea></affiliation></author><author><name sortKey="Villette, Sylviane" sort="Villette, Sylviane" uniqKey="Villette S" first="Sylviane" last="Villette">Sylviane Villette</name><affiliation wicri:level="1"><nlm:aff id="aff011">Department of Radiation Oncology,<institution>René Huguenin Center</institution>,<addr-line>Saint-Cloud, France</addr-line></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Saint-Cloud</wicri:regionArea></affiliation></author><author><name sortKey="Vees, Hansjorg" sort="Vees, Hansjorg" uniqKey="Vees H" first="Hansjörg" last="Vees">Hansjörg Vees</name><affiliation><nlm:aff id="aff003">Department of Radiation Oncology,<institution>University Hospital Geneva</institution>,<addr-line>Switzerland</addr-line></nlm:aff></affiliation></author></analytic><series><title level="j">Rare Tumors</title><idno type="ISSN">2036-3605</idno><idno type="eISSN">2036-3613</idno><imprint><date when="2016">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Uterine carcinosarcomas (UCS) are rare tumors. Consensus regarding therapeutic management in non-metastatic disease is lacking. This study reports on outcome and predictive factors when using postoperative radiotherapy. We analyzed a retrospective analysis in 124 women treated between 1987-2007 in the framework of the Rare-Cancer-Network. Median follow-up was 27 months. Postoperative pelvic EBRT was administered in 105 women (85%) and 92 patients (74%) received exclusive or additional vaginal brachytherapy. Five-year overall survival (OS), disease-free survival (DFS), cancer specific survival (CSS) and locoregional control (LRC) were 51.6% (95% CI 35-73%), 53.7% (39-71%), 58.6% (38-74%) and 48% (38-67%). Multivariate analysis showed that external beam radiation therapy (EBRT) >50Gy was an independent prognostic factor for better OS (P=0.03), CSS (P=0.02) and LRC (P=0.01). Relative risks (RR) for better OS (P=0.02), DFS (P=0.04) and LRC (P=0.01) were significantly associated with younger age (≤60 years). Higher brachytherapy (BT)-dose (>9Gy) improved DFS (P=0.04) and LRC (P=0.008). We concluded that UCS has high systemic failure rate. Local relapse was reduced by a relative risk factor of over three in all stages of diseases when using higher doses for EBRT and brachytherapy. Postoperative RT was most effective in UCS stage I/II-diseases.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Arend, R" uniqKey="Arend R">R Arend</name></author><author><name sortKey="Doneza, Ja" uniqKey="Doneza J">JA Doneza</name></author><author><name sortKey="Wright, Jd" uniqKey="Wright J">JD. Wright</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Prat, J" uniqKey="Prat J">J. Prat</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gadducci, A" uniqKey="Gadducci A">A Gadducci</name></author><author><name sortKey="Cosio, S" uniqKey="Cosio S">S Cosio</name></author><author><name sortKey="Romanini, A" uniqKey="Romanini A">A Romanini</name></author><author><name sortKey="Genazzani, Ar" uniqKey="Genazzani A">AR. Genazzani</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Moe, Mm" uniqKey="Moe M">MM Moe</name></author><author><name sortKey="El Sharkawi, S" uniqKey="El Sharkawi S">S. El-Sharkawi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Callister, M" uniqKey="Callister M">M Callister</name></author><author><name sortKey="Ramondetta, Lm" uniqKey="Ramondetta L">LM Ramondetta</name></author><author><name sortKey="Jhingran, A" uniqKey="Jhingran A">A Jhingran</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gadducci, A" uniqKey="Gadducci A">A Gadducci</name></author><author><name sortKey="Sartori, E" uniqKey="Sartori E">E Sartori</name></author><author><name sortKey="Landoni, F" uniqKey="Landoni F">F Landoni</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ho, Kc" uniqKey="Ho K">KC Ho</name></author><author><name sortKey="Lai, Ch" uniqKey="Lai C">CH Lai</name></author><author><name sortKey="Wu, Ti" uniqKey="Wu T">TI Wu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Inthasorn, P" uniqKey="Inthasorn P">P Inthasorn</name></author><author><name sortKey="Carter, J" uniqKey="Carter J">J Carter</name></author><author><name sortKey="Valmadre, S" uniqKey="Valmadre S">S Valmadre</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sampath, S" uniqKey="Sampath S">S Sampath</name></author><author><name sortKey="Schultheiss, Te" uniqKey="Schultheiss T">TE Schultheiss</name></author><author><name sortKey="Ryu, Jk" uniqKey="Ryu J">JK Ryu</name></author><author><name sortKey="Wong, Jy" uniqKey="Wong J">JY. Wong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wolfson, Ah" uniqKey="Wolfson A">AH Wolfson</name></author><author><name sortKey="Brady, Mf" uniqKey="Brady M">MF Brady</name></author><author><name sortKey="Rocereto, T" uniqKey="Rocereto T">T Rocereto</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Reed, Ns" uniqKey="Reed N">NS Reed</name></author><author><name sortKey="Mangioni, C" uniqKey="Mangioni C">C Mangioni</name></author><author><name sortKey="Malmstrom, H" uniqKey="Malmstrom H">H Malmström</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brown, Lc" uniqKey="Brown L">LC Brown</name></author><author><name sortKey="Petersen, Ia" uniqKey="Petersen I">IA Petersen</name></author><author><name sortKey="Haddock, Mg" uniqKey="Haddock M">MG Haddock</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Patel, N" uniqKey="Patel N">N Patel</name></author><author><name sortKey="Hegarty, Se" uniqKey="Hegarty S">SE Hegarty</name></author><author><name sortKey="Cantrell, La" uniqKey="Cantrell L">LA Cantrell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Harano, K" uniqKey="Harano K">K Harano</name></author><author><name sortKey="Hirakawa, A" uniqKey="Hirakawa A">A Hirakawa</name></author><author><name sortKey="Yunokawa, M" uniqKey="Yunokawa M">M Yunokawa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ghaemmaghami, F" uniqKey="Ghaemmaghami F">F Ghaemmaghami</name></author><author><name sortKey="Karimi Zarchi, M" uniqKey="Karimi Zarchi M">M Karimi-Zarchi</name></author><author><name sortKey="Gilani, Mm" uniqKey="Gilani M">MM Gilani</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Livi, L" uniqKey="Livi L">L Livi</name></author><author><name sortKey="Paiar, F" uniqKey="Paiar F">F Paiar</name></author><author><name sortKey="Shah, N" uniqKey="Shah N">N Shah</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Major, Fj" uniqKey="Major F">FJ Major</name></author><author><name sortKey="Blessing, Ja" uniqKey="Blessing J">JA Blessing</name></author><author><name sortKey="Silverberg, Sg" uniqKey="Silverberg S">SG Silverberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vongtama, V" uniqKey="Vongtama V">V Vongtama</name></author><author><name sortKey="Karlen, Jr" uniqKey="Karlen J">JR Karlen</name></author><author><name sortKey="Piver, Sm" uniqKey="Piver S">SM Piver</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sorbe, B" uniqKey="Sorbe B">B Sorbe</name></author><author><name sortKey="Johansson, B" uniqKey="Johansson B">B. Johansson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nout, Ra" uniqKey="Nout R">RA Nout</name></author><author><name sortKey="Van De Poll Franse, Lv" uniqKey="Van De Poll Franse L">LV van de Poll-Franse</name></author><author><name sortKey="Lybeert, M" uniqKey="Lybeert M">M Lybeert</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yoney, A" uniqKey="Yoney A">A Yoney</name></author><author><name sortKey="Eren, B" uniqKey="Eren B">B Eren</name></author><author><name sortKey="Eskici, S" uniqKey="Eskici S">S Eskici</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hoffmann, W" uniqKey="Hoffmann W">W Hoffmann</name></author><author><name sortKey="Schmandt, S" uniqKey="Schmandt S">S Schmandt</name></author><author><name sortKey="Kortmann, Rd" uniqKey="Kortmann R">RD Kortmann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nout, Ra" uniqKey="Nout R">RA Nout</name></author><author><name sortKey="Smit, Vt" uniqKey="Smit V">VT Smit</name></author><author><name sortKey="Putter, H" uniqKey="Putter H">H Putter</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Herrera, Fg" uniqKey="Herrera F">FG Herrera</name></author><author><name sortKey="Cruz, Os" uniqKey="Cruz O">OS Cruz</name></author><author><name sortKey="Achtari, C" uniqKey="Achtari C">C Achtari</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Clayton Smith, D" uniqKey="Clayton Smith D">D Clayton Smith</name></author><author><name sortKey="Kenneth Macdonald, O" uniqKey="Kenneth Macdonald O">O Kenneth Macdonald</name></author><author><name sortKey="Gaffney, Dk" uniqKey="Gaffney D">DK. Gaffney</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nemani, D" uniqKey="Nemani D">D Nemani</name></author><author><name sortKey="Mitra, N" uniqKey="Mitra N">N Mitra</name></author><author><name sortKey="Guo, M" uniqKey="Guo M">M Guo</name></author><author><name sortKey="Lin, L" uniqKey="Lin L">L. Lin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sampath, S" uniqKey="Sampath S">S Sampath</name></author><author><name sortKey="Gaffney, Dk" uniqKey="Gaffney D">DK. Gaffney</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Denschlag, D" uniqKey="Denschlag D">D Denschlag</name></author><author><name sortKey="Masoud, I" uniqKey="Masoud I">I Masoud</name></author><author><name sortKey="Stanimir, G" uniqKey="Stanimir G">G Stanimir</name></author><author><name sortKey="Gilbert, L" uniqKey="Gilbert L">L. Gilbert</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sartori, E" uniqKey="Sartori E">E Sartori</name></author><author><name sortKey="Bazzurini, L" uniqKey="Bazzurini L">L Bazzurini</name></author><author><name sortKey="Gadducci, A" uniqKey="Gadducci A">A Gadducci</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Rare Tumors</journal-id><journal-id journal-id-type="iso-abbrev">Rare Tumors</journal-id><journal-id journal-id-type="publisher-id">RT</journal-id><journal-title-group><journal-title>Rare Tumors</journal-title></journal-title-group><issn pub-type="ppub">2036-3605</issn><issn pub-type="epub">2036-3613</issn><publisher><publisher-name>PAGEPress Publications, Pavia, Italy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27441069</article-id><article-id pub-id-type="pmc">4935818</article-id><article-id pub-id-type="doi">10.4081/rt.2016.6052</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Outcome and Predictive Factors in Uterine Carcinosarcoma Using Postoperative Radiotherapy: A Rare Cancer Network Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zwahlen</surname><given-names>Daniel R.</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Schick</surname><given-names>Ulrike</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bolukbasi</surname><given-names>Yasemin</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Thariat</surname><given-names>Juliette</given-names></name><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Abdah-Bortnyak</surname><given-names>Roxolyana</given-names></name><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kuten</surname><given-names>Abraham</given-names></name><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Igdem</surname><given-names>Sefik</given-names></name><xref ref-type="aff" rid="aff007"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Caglar</surname><given-names>Hale</given-names></name><xref ref-type="aff" rid="aff008"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ozsaran</surname><given-names>Zeynep</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Loessl</surname><given-names>Kristina</given-names></name><xref ref-type="aff" rid="aff009"><sup>9</sup></xref></contrib><contrib contrib-type="author"><name><surname>Belkaaloul</surname><given-names>Kaouthar Khanfir</given-names></name><xref ref-type="aff" rid="aff010"><sup>10</sup></xref></contrib><contrib contrib-type="author"><name><surname>Villette</surname><given-names>Sylviane</given-names></name><xref ref-type="aff" rid="aff011"><sup>11</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vees</surname><given-names>Hansjörg</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1"></xref></contrib></contrib-group><aff id="aff001"><label>1</label>Department of Radiation Oncology,<institution>Kantonsspital Graubuenden</institution>,<addr-line>Chur, Switzerland</addr-line></aff><aff id="aff002"><label>2</label>Department of Radiation Oncology,<institution>William Buckland Radiotherapy Centre, Alfred Health</institution>,<addr-line>Melbourne, Australia</addr-line></aff><aff id="aff003"><label>3</label>Department of Radiation Oncology,<institution>University Hospital Geneva</institution>,<addr-line>Switzerland</addr-line></aff><aff id="aff004"><label>4</label>Department of Radiation Oncology,<institution>Ege University Hospital</institution>,<addr-line>Izmir, Turkey</addr-line></aff><aff id="aff005"><label>5</label>Department of Radiation Oncology,<institution>Antoine Lacassagne Center</institution>,<addr-line>Nice, France</addr-line></aff><aff id="aff006"><label>6</label>Department of Radiation Oncology,<institution>Rambam Medical Center</institution>,<addr-line>Haifa, Israel</addr-line></aff><aff id="aff007"><label>7</label>Department of Radiation Oncology,<institution>Metropolitan Hospital</institution>,<addr-line>Istanbul, Turkey</addr-line></aff><aff id="aff008"><label>8</label>Department of Radiation Oncology,<institution>Marmara University Hospital</institution>,<addr-line>Istanbul, Turkey</addr-line></aff><aff id="aff009"><label>9</label>Department of Radiation Oncology,<institution>University Hospital</institution>,<addr-line>Bern, Switzerland</addr-line></aff><aff id="aff010"><label>10</label>Department of Radiation Oncology,<institution>Hôpital du Valais</institution>,<addr-line>Sion, Switzerland</addr-line></aff><aff id="aff011"><label>11</label>Department of Radiation Oncology,<institution>René Huguenin Center</institution>,<addr-line>Saint-Cloud, France</addr-line></aff><author-notes><corresp id="cor1">Institute for Radiotherapy, Hirslanden Klinik, Witellikerstrasse 40, CH-8032 Zürich, Switzerland. <phone>+41.44.9224410</phone> - <fax>+41.44.9224423</fax>. <email>hansjoerg.vees@hirslanden.ch</email></corresp><fn fn-type="con"><p>Contributions: DRZ, data collection, data analysis and article writing; US, data collection and data analysis; YB, JT, RAB, AK, SI, HC, ZO, KL, KKB, and SV, data collection; HV, data analysis, statistics and article writing. DRZ and HV contributed equally to this publication</p></fn><fn fn-type="conflict"><p>Conflict of interest: the authors declare no potential conflict of interest.</p></fn></author-notes><pub-date pub-type="epub"><day>29</day><month>6</month><year>2016</year></pub-date><pub-date pub-type="collection"><day>28</day><month>6</month><year>2016</year></pub-date><volume>8</volume><issue>2</issue><elocation-id>6052</elocation-id><history><date date-type="received"><day>08</day><month>6</month><year>2015</year></date><date date-type="rev-recd"><day>06</day><month>8</month><year>2015</year></date><date date-type="accepted"><day>07</day><month>8</month><year>2015</year></date></history><permissions><copyright-statement>©Copyright D.R. Zwahlen et al.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Licensee PAGEPress, Italy</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<uri xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</uri>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Uterine carcinosarcomas (UCS) are rare tumors. Consensus regarding therapeutic management in non-metastatic disease is lacking. This study reports on outcome and predictive factors when using postoperative radiotherapy. We analyzed a retrospective analysis in 124 women treated between 1987-2007 in the framework of the Rare-Cancer-Network. Median follow-up was 27 months. Postoperative pelvic EBRT was administered in 105 women (85%) and 92 patients (74%) received exclusive or additional vaginal brachytherapy. Five-year overall survival (OS), disease-free survival (DFS), cancer specific survival (CSS) and locoregional control (LRC) were 51.6% (95% CI 35-73%), 53.7% (39-71%), 58.6% (38-74%) and 48% (38-67%). Multivariate analysis showed that external beam radiation therapy (EBRT) >50Gy was an independent prognostic factor for better OS (P=0.03), CSS (P=0.02) and LRC (P=0.01). Relative risks (RR) for better OS (P=0.02), DFS (P=0.04) and LRC (P=0.01) were significantly associated with younger age (≤60 years). Higher brachytherapy (BT)-dose (>9Gy) improved DFS (P=0.04) and LRC (P=0.008). We concluded that UCS has high systemic failure rate. Local relapse was reduced by a relative risk factor of over three in all stages of diseases when using higher doses for EBRT and brachytherapy. Postoperative RT was most effective in UCS stage I/II-diseases.</p></abstract><kwd-group><title>Key words</title><kwd>Carcinosarcoma</kwd><kwd>uterine malignancies</kwd><kwd>radiotherapy</kwd><kwd>brachytherapy</kwd><kwd>toxicity</kwd></kwd-group><counts><fig-count count="1"></fig-count><table-count count="3"></table-count><equation-count count="0"></equation-count><ref-count count="30"></ref-count><page-count count="7"></page-count></counts></article-meta></front><floats-group><fig id="fig001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Five-year overall survival rates (A) and disease-free survival rates (B) in patients presenting with uterine carcinosarcoma.</p></caption><graphic xlink:href="rt-2016-2-6052-g001"></graphic></fig><table-wrap id="table001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Patient, tumor and treatment characteristics.</p></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Characteristic</th><th align="center" valign="top" rowspan="1" colspan="1">N=124</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age years, median (range)</td><td align="center" valign="top" rowspan="1" colspan="1">66.5 (50-88)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Postmenopausal status</td><td align="center" valign="top" rowspan="1" colspan="1">116(94)</td></tr><tr><td align="left" valign="top" colspan="2" rowspan="1">Symptoms at diagnosis</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Bleeding</td><td align="center" valign="top" rowspan="1" colspan="1">102(82)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Pain</td><td align="center" valign="top" rowspan="1" colspan="1">18(15)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Tamoxifen intake history</td><td align="center" valign="top" rowspan="1" colspan="1">17(14)</td></tr><tr><td align="left" valign="top" colspan="2" rowspan="1">FIGO Stage (2009)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> IA</td><td align="center" valign="top" rowspan="1" colspan="1">38(30)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> IB</td><td align="center" valign="top" rowspan="1" colspan="1">26(21)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> II</td><td align="center" valign="top" rowspan="1" colspan="1">17(14)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> All stage I/II</td><td align="center" valign="top" rowspan="1" colspan="1">81(65)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> IIIA</td><td align="center" valign="top" rowspan="1" colspan="1">17(14)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> IIIB</td><td align="center" valign="top" rowspan="1" colspan="1">3(2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> IIIC</td><td align="center" valign="top" rowspan="1" colspan="1">15(12)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> IV</td><td align="center" valign="top" rowspan="1" colspan="1">4(3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> All stage III/IV</td><td align="center" valign="top" rowspan="1" colspan="1">39(32)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Unknown</td><td align="center" valign="top" rowspan="1" colspan="1">4(3)</td></tr><tr><td align="left" valign="top" colspan="2" rowspan="1">Surgery</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Hysterectomy</td><td align="center" valign="top" rowspan="1" colspan="1">124</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Salpingo-oophorectomy</td><td align="center" valign="top" rowspan="1" colspan="1">122(98)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Pelvic nodal evaluation</td><td align="center" valign="top" rowspan="1" colspan="1">76(61)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Positive margin</td><td align="center" valign="top" rowspan="1" colspan="1">12(9) [20 pts without info concerning margins]</td></tr><tr><td align="left" valign="top" colspan="2" rowspan="1">Radiation therapy</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> No adjuvant RT</td><td align="center" valign="top" rowspan="1" colspan="1">13(10)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Adjuvant RT</td><td align="center" valign="top" rowspan="1" colspan="1">111(90)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> EBRT only</td><td align="center" valign="top" rowspan="1" colspan="1">19(15)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> EBRT+BT</td><td align="center" valign="top" rowspan="1" colspan="1">86(69)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> BT only</td><td align="center" valign="top" rowspan="1" colspan="1">6(3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Interruption >5 days</td><td align="center" valign="top" rowspan="1" colspan="1">14(11)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mean EBRT dose (Gy)</td><td align="center" valign="top" rowspan="1" colspan="1">48.4 (range, 9-59 Gy, median 50.4 Gy)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mean BT dose (Gy)</td><td align="center" valign="top" rowspan="1" colspan="1">16.1 (range, 6-34 Gy, median 16.0 Gy)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Adjuvant chemotherapy</td><td align="center" valign="top" rowspan="1" colspan="1">25(20)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hormonal treatment</td><td align="center" valign="top" rowspan="1" colspan="1">13(10)</td></tr></tbody></table><table-wrap-foot><fn><p>FIGO, International Federation of Gynecology and Obstetrics; RT, Radiation therapy; EBRT, External beam radiation therapy; BT, Brachytherapy; pts, Patients. Values are numbers (percentage) unless otherwise noted.</p></fn></table-wrap-foot></table-wrap><table-wrap id="table002" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Analysis of predictive factors for overall survival, cancer-specific survival, disease-free survival and locoregional control.</p></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">5-year outcome</th><th align="center" valign="top" rowspan="1" colspan="1">OS 51.6%<break></break>(95%CI 35-73%)</th><th align="center" valign="top" rowspan="1" colspan="1">CSS 58.6%<break></break>(95%CI 38-74%)</th><th align="center" valign="top" rowspan="1" colspan="1">DFS 53.7%<break></break>(95%CI 39-71%)</th><th align="center" valign="top" rowspan="1" colspan="1">LRC 48.0%<break></break>(95%CI 38-67%)</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="5" rowspan="1">Multivariate analysis, P-value (RR)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> PLND</td><td align="center" valign="top" rowspan="1" colspan="1">0.08 (1.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.03 (2.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.03 (2.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.05 (2.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Dose EBRT >50 Gy</td><td align="center" valign="top" rowspan="1" colspan="1">0.03 (2.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.02 (2.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0.06 (1.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.01 (3.6)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Dose BT ≤9Gy <italic>vs</italic>. ≥9Gy</td><td align="center" valign="top" rowspan="1" colspan="1">0.1 (1.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.08 (1.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.04 (2.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.008 (5.1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> FIGO stage I-II <italic>vs</italic>. III-IV</td><td align="center" valign="top" rowspan="1" colspan="1">0.01 (3.3)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">0.03 (2.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.07 (1.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Age ≤60 <italic>vs.</italic> ≥ 60 years</td><td align="center" valign="top" rowspan="1" colspan="1">0.02 (3.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.05 (1.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.04 (2.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0.01 (4.3)</td></tr><tr><td align="left" valign="top" colspan="5" rowspan="1">Univariate analysis %, P value (95 CI)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Chemotherapy</td><td align="center" valign="top" rowspan="1" colspan="1">0.15 (24-79)</td><td align="center" valign="top" rowspan="1" colspan="1">0.64 (33-81)</td><td align="center" valign="top" rowspan="1" colspan="1">0.29 (38-70)</td><td align="center" valign="top" rowspan="1" colspan="1">0.23 (34-71)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> PLND</td><td align="center" valign="top" rowspan="1" colspan="1">0.1 (36-73)</td><td align="center" valign="top" rowspan="1" colspan="1">0.01 (31-77)</td><td align="center" valign="top" rowspan="1" colspan="1">0.02 (33-72)</td><td align="center" valign="top" rowspan="1" colspan="1">0.01 (26-63)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Dose Brachytherapy</td><td align="center" valign="top" rowspan="1" colspan="1">0.01 (32-76)</td><td align="center" valign="top" rowspan="1" colspan="1">0.04 (36-75)</td><td align="center" valign="top" rowspan="1" colspan="1"><0.001 (36-71)</td><td align="center" valign="top" rowspan="1" colspan="1"><0.001 (30-76)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Surgical resection margin</td><td align="center" valign="top" rowspan="1" colspan="1">0.32 (27-84)</td><td align="center" valign="top" rowspan="1" colspan="1">0.17 (30-76)</td><td align="center" valign="top" rowspan="1" colspan="1">0.39 (37-74)</td><td align="center" valign="top" rowspan="1" colspan="1">0.28 (36-69)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Pelvic lymph node RT</td><td align="center" valign="top" rowspan="1" colspan="1">0.42 (37-76)</td><td align="center" valign="top" rowspan="1" colspan="1">0.61 (30-69)</td><td align="center" valign="top" rowspan="1" colspan="1">0.56 (37-70)</td><td align="center" valign="top" rowspan="1" colspan="1">0.12 (29-72)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> RT treatment interruption >5 days</td><td align="center" valign="top" rowspan="1" colspan="1">0.45 (38-81)</td><td align="center" valign="top" rowspan="1" colspan="1">0.72 (37-80)</td><td align="center" valign="top" rowspan="1" colspan="1">0.68 (36-71)</td><td align="center" valign="top" rowspan="1" colspan="1">0.22 (38-81)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> EBRT</td><td align="center" valign="top" rowspan="1" colspan="1">0.91 (38-74)</td><td align="center" valign="top" rowspan="1" colspan="1">0.82 (34-76)</td><td align="center" valign="top" rowspan="1" colspan="1">0.88 (38-73)</td><td align="center" valign="top" rowspan="1" colspan="1">0.76 (23-73)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Premenopausal status</td><td align="center" valign="top" rowspan="1" colspan="1">0.14 (29-74)</td><td align="center" valign="top" rowspan="1" colspan="1">0.20 (26-77)</td><td align="center" valign="top" rowspan="1" colspan="1">0.10 (37-70)</td><td align="center" valign="top" rowspan="1" colspan="1">0.12 (34-71)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Dose postoperative RT</td><td align="center" valign="top" rowspan="1" colspan="1"><0.001 (30-71)</td><td align="center" valign="top" rowspan="1" colspan="1">0.009 (32-79)</td><td align="center" valign="top" rowspan="1" colspan="1"><0.001 (34-62)</td><td align="center" valign="top" rowspan="1" colspan="1"><0.001 (23-66)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Stage I/II <italic>vs.</italic> III/IV</td><td align="center" valign="top" rowspan="1" colspan="1">0.04 (30-76)</td><td align="center" valign="top" rowspan="1" colspan="1">0.05 (28-75)</td><td align="center" valign="top" rowspan="1" colspan="1">0.04 (32-68)</td><td align="center" valign="top" rowspan="1" colspan="1">0.04 (31-70)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Age at diagnosis</td><td align="center" valign="top" rowspan="1" colspan="1">0.02 (33-74)</td><td align="center" valign="top" rowspan="1" colspan="1">0.04 (27-78)</td><td align="center" valign="top" rowspan="1" colspan="1">0.01 (36-63)</td><td align="center" valign="top" rowspan="1" colspan="1">0.02 (34-67)</td></tr></tbody></table><table-wrap-foot><fn><p>OS, overall survival; CSS, cancer-specific survival; DFS, disease-free survival; LRC, locoregional control; RR, relative risk; PLND, pelvic lymph node dissection; CI, confidence interval; Other abbreviations as in <xref ref-type="table" rid="table001">Table 1</xref>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="table003" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Selected studies reporting outcome and prognostic factors in uterine carcinosarcomas.</p></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Author/year</th><th align="left" valign="top" rowspan="1" colspan="1">Year, n.</th><th align="left" valign="top" rowspan="1" colspan="1">Median age, y</th><th align="left" valign="top" rowspan="1" colspan="1">FIGO stage</th><th align="left" valign="top" rowspan="1" colspan="1">Positive surgical margin</th><th align="left" valign="top" rowspan="1" colspan="1">Median FU, months</th><th align="left" valign="top" rowspan="1" colspan="1">LAD</th><th align="left" valign="top" rowspan="1" colspan="1">Adjuvant treatment</th><th align="left" valign="top" rowspan="1" colspan="1"><break></break>OS</th><th align="left" valign="top" rowspan="1" colspan="1"><break></break>DFS</th><th align="left" valign="top" rowspan="1" colspan="1"><break></break>CSS</th><th align="left" valign="top" rowspan="1" colspan="1"><break></break>LRC</th><th align="left" valign="top" rowspan="1" colspan="1">Outcome factors</th></tr><tr><th align="left" valign="top" colspan="13" rowspan="1">Randomized prospective studies</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Reed 2008<sup><xref rid="ref12" ref-type="bibr">12</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">1988-2001. 92/224</td><td align="left" valign="top" rowspan="1" colspan="1">59 whole study population</td><td align="left" valign="top" rowspan="1" colspan="1">NR tor subgroup UCS (98.2% of whole study population had stage 1 and 11)</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">81.6 (whole study population)</td><td align="left" valign="top" rowspan="1" colspan="1">NR for subgroup UCS (74.1% of whole study population had no LAD)</td><td align="left" valign="top" rowspan="1" colspan="1">Randomized: RT: 47 pts, No RT: 45 pts</td><td align="left" valign="top" rowspan="1" colspan="1">5y: whole study population median survival time (y): RT: 8.53; No RT: 6.78; n.s.</td><td align="left" valign="top" rowspan="1" colspan="1">5y: whole study population RT:51% No RT: 49%; n.s.</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">5y: RT:61% No RT: 47%</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Wolfson 2007<sup><xref rid="ref11" ref-type="bibr">11</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">1993-2005, 206</td><td align="left" valign="top" rowspan="1" colspan="1">68</td><td align="left" valign="top" rowspan="1" colspan="1">I:31%, II:13%, III: 45%, IV: 12%</td><td align="left" valign="top" rowspan="1" colspan="1">5.0% (gross residual disease)</td><td align="left" valign="top" rowspan="1" colspan="1">5.3</td><td align="left" valign="top" rowspan="1" colspan="1">NR RT</td><td align="left" valign="top" rowspan="1" colspan="1">Randomized: (whole abdominial irradiation): 105 pts, No RT (but ChT): 101 pts</td><td align="left" valign="top" rowspan="1" colspan="1">5y: RT: 35%; No RT: 45%; n.s.</td><td align="left" valign="top" rowspan="1" colspan="1">5y: RT:42%, No RT: 48%</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" colspan="13" rowspan="1"><bold>Retrospective studies</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Vongtama 1976<sup><xref rid="ref19" ref-type="bibr">19</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">1945-1972, 27/115</td><td align="left" valign="top" rowspan="1" colspan="1">58 (mean) whole study population</td><td align="left" valign="top" rowspan="1" colspan="1">I:81%, II:19%</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">Sx:10 pts;Sx + RT: 14 pts; RT alone: 3 pts</td><td align="left" valign="top" rowspan="1" colspan="1">5y Sx:36% Sx+RT: 57%; RT alone: 0%</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">Adjuvant RT for OS</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Major 1993<sup><xref rid="ref18" ref-type="bibr">18</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">1979-1988, 301/453</td><td align="left" valign="top" rowspan="1" colspan="1">66</td><td align="left" valign="top" rowspan="1" colspan="1">I:59%, II:21%, III: 9%, IV: 11%</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">95%</td><td align="left" valign="top" rowspan="1" colspan="1">Sx: 182 pts; Sx + RT: 119 pts</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">Crude rate, Sx: 43 pts, Rx+RT: 20 pts</td><td align="left" valign="top" rowspan="1" colspan="1">Progression-tree survival: Lymph adnexal involvement, histologic grade of sarcoma</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sartori 1997<sup><xref rid="ref30" ref-type="bibr">30</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">1980-1994, 118</td><td align="left" valign="top" rowspan="1" colspan="1">67</td><td align="left" valign="top" rowspan="1" colspan="1">I:47%, II:9%, III: 23.5%, IV: 18% No Sx: 2.5%</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">66</td><td align="left" valign="top" rowspan="1" colspan="1">40%</td><td align="left" valign="top" rowspan="1" colspan="1">FIGO stage 1/11; Sx + RT: 28 pts; Sx: 33 pts; Sx + ChT: 5 pts</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">5y: Sx+RT: 53% Sx: 50%, n.s.</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">At closure of study 59%</td><td align="left" valign="top" rowspan="1" colspan="1">Sx</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Brown 2015<sup><xref rid="ref15" ref-type="bibr">15</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">2000-2013, 33</td><td align="left" valign="top" rowspan="1" colspan="1">68</td><td align="left" valign="top" rowspan="1" colspan="1">I:97%, II:3%</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">24</td><td align="left" valign="top" rowspan="1" colspan="1">Pelvis: 82%, para-aortic: 42%</td><td align="left" valign="top" rowspan="1" colspan="1">BT: 100%; ChT: 55%</td><td align="left" valign="top" rowspan="1" colspan="1">2y: 79%</td><td align="left" valign="top" rowspan="1" colspan="1">66%</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">81%</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Patel 2015<sup><xref rid="ref13" ref-type="bibr">13</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">1998-2010, 1581</td><td align="left" valign="top" rowspan="1" colspan="1"><55:12.7%, 55-64:32%, 65-75:30.8% 75+: 24.5%</td><td align="left" valign="top" rowspan="1" colspan="1">I:86.7%, II:13.3%</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">Sx: 50.8%; Sx + EBRT ± BT: 40.2% Sx + BT alone: 9%</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">higher rates of OS and CSS:younger age at diagnosis. FIGOI (vs. II)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Harano 2015<sup><xref rid="ref14" ref-type="bibr">14</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">2007-2012, 486</td><td align="left" valign="top" rowspan="1" colspan="1">65</td><td align="left" valign="top" rowspan="1" colspan="1">I:46%, II:7%, III: 28%, IV: 19%</td><td align="left" valign="top" rowspan="1" colspan="1">Residual tumor <1 cm: 87%, >1 cm: 11%, unknown: 2%</td><td align="left" valign="top" rowspan="1" colspan="1">23.1</td><td align="left" valign="top" rowspan="1" colspan="1">Pelvis: 56%, Para-aortic: 23%</td><td align="left" valign="top" rowspan="1" colspan="1">Sx + ChT: 91%; Sx + RT: 2%; Sx + RT/ChT: 1%; Observation: 6%</td><td align="left" valign="top" rowspan="1" colspan="1">5y: whole study population 53.6%; I:69.9%, II:64.4%,III:43.5%, IV: 25.3%</td><td align="left" valign="top" rowspan="1" colspan="1">5y: whole study population 40.4%, I:59.4%, II:52.4%, III:25.6%, IV: 12.3%</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">Poor prognosis: Stage, performance status, CA-125 level, Lymphovascular invasion, myometrial invasion, Good prognosis: pelvic LAD</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Livi 2003<sup><xref rid="ref17" ref-type="bibr">17</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">1974-2001, 42/141</td><td align="left" valign="top" rowspan="1" colspan="1">56</td><td align="left" valign="top" rowspan="1" colspan="1">NR tor subgroup UCS. I:50.5%, II:9%, III: 22%, IV: 18.5%</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">36</td><td align="left" valign="top" rowspan="1" colspan="1">Not performed in any patient</td><td align="left" valign="top" rowspan="1" colspan="1">Whole study population: Sx: 25.5%; Sx + RT: 52.5%</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">5y: with stage I: Sx: 15%, Sx + ChT: 43% Sx + RT: 70% with stage III, Sx: 40%, Sx + RT + BT: 85.8%</td><td align="left" valign="top" rowspan="1" colspan="1">5y: NR for UCS; whole study population 27.7%</td><td align="left" valign="top" rowspan="1" colspan="1">3y: Sx:38%; Sx + RT: 69% Sx + RT + BT: 72%, Sx + ChT: 29%</td><td align="left" valign="top" rowspan="1" colspan="1">Stage, histology adjuvant RT >50 Gy (P=0.001)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Callister 2004<sup><xref rid="ref6" ref-type="bibr">6</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">1954-1998, 300</td><td align="left" valign="top" rowspan="1" colspan="1">64</td><td align="left" valign="top" rowspan="1" colspan="1">I:64%, II:21%, III:10</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">109</td><td align="left" valign="top" rowspan="1" colspan="1">39%</td><td align="left" valign="top" rowspan="1" colspan="1">Sx: 38%; Sx + RT: 53%; RT alone: 9%; Additional ChT: 16%</td><td align="left" valign="top" rowspan="1" colspan="1">5y:31%</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">5y: 33%</td><td align="left" valign="top" rowspan="1" colspan="1">5y: 62% pelvis control</td><td align="left" valign="top" rowspan="1" colspan="1">Adjuvant RT</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Denschlag 2007<sup><xref rid="ref29" ref-type="bibr">29</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">1989-2004, 36/94</td><td align="left" valign="top" rowspan="1" colspan="1">60</td><td align="left" valign="top" rowspan="1" colspan="1">I:42%, II:14%, III: 17%, IV: 6%</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">48</td><td align="left" valign="top" rowspan="1" colspan="1">74% whole study population</td><td align="left" valign="top" rowspan="1" colspan="1">Sx + RT: 15pts; Sx + RT + ChT: 13 pts</td><td align="left" valign="top" rowspan="1" colspan="1">5y: 47%, whole study population</td><td align="left" valign="top" rowspan="1" colspan="1">5y: 41%, whole study population</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">OS: Age, P=0.0015, adjuvant RT tor UCS, P=0.003</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Clayton Smith 2008<sup><xref rid="ref26" ref-type="bibr">26</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">1973-2003, 2461</td><td align="left" valign="top" rowspan="1" colspan="1">70</td><td align="left" valign="top" rowspan="1" colspan="1">I-IV</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">47</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">RT: 36%; Sx: 64%</td><td align="left" valign="top" rowspan="1" colspan="1">5y: RT: 42.2%, Sx: 33.1%</td><td align="left" valign="top" rowspan="1" colspan="1">5y: (Uterine specific survival), RT: 56.7%, Sx: 50.7%</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">Adjuvant RT</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ghaemmaghami 2008<sup><xref rid="ref16" ref-type="bibr">16</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">1999-2004, 17/57</td><td align="left" valign="top" rowspan="1" colspan="1">50</td><td align="left" valign="top" rowspan="1" colspan="1">NR tor subgroup UCS, whole study population, I:52.5%, II:16%, III: 21%, IV: 10.5%</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">19</td><td align="left" valign="top" rowspan="1" colspan="1">UCS: 64%</td><td align="left" valign="top" rowspan="1" colspan="1">UCS: Sx: 17 pts; Sx+RT: 1 pt; (Sx + RT: whole study population: 14 pts)</td><td align="left" valign="top" rowspan="1" colspan="1">5y:52%, whole study population: UCS, 41%</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">5y: 75% whole study population</td><td align="left" valign="top" rowspan="1" colspan="1">Stage, histology, grading, Local control: adjvant RT >50 Gy</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sorbe 2008<sup><xref rid="ref20" ref-type="bibr">20</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">1975-2003, 60/155</td><td align="left" valign="top" rowspan="1" colspan="1">64.5 (mean) whole study population</td><td align="left" valign="top" rowspan="1" colspan="1">NR tor subgroup UCS, whole study population, I:61%, II:6%, III:17%, IV: 15%</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">160 whole study population</td><td align="left" valign="top" rowspan="1" colspan="1">7.1.% whole study population</td><td align="left" valign="top" rowspan="1" colspan="1">Stage I, II:40 pts; Sx: 4 pts; Sx + RT: 36 pts</td><td align="left" valign="top" rowspan="1" colspan="1">5y: NR for UCS; whole study population 42%</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">Crude rate Sx: 3 pts, Sx + RT: 28 pts</td><td align="left" valign="top" rowspan="1" colspan="1">Tumor stage, histology, number of mitoses</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Nemani 2008<sup><xref rid="ref21" ref-type="bibr">21</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">1988-2003, 1855</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">I:65%, II:14%, III: 21%</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">57%</td><td align="left" valign="top" rowspan="1" colspan="1">Sx: 939; Sx + RT: 653 pts</td><td align="left" valign="top" rowspan="1" colspan="1">5y: no lymph node dissection; Sx: 33%, Sx + RT: 36%</td><td align="left" valign="top" rowspan="1" colspan="1">5y: improved with RT</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">Lymph node dissection</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sampath 2010<sup><xref rid="ref10" ref-type="bibr">10</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">1980-2005, 1877/3650</td><td align="left" valign="top" rowspan="1" colspan="1">64</td><td align="left" valign="top" rowspan="1" colspan="1">NR tor subgroup UCS, I: 30%, II:7%, III: 12%, IV: 13.5%, unknown: 37.5%</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">59.3</td><td align="left" valign="top" rowspan="1" colspan="1">Node positive: 7.9%; node negative: 51.6%, unknown; 40.5%</td><td align="left" valign="top" rowspan="1" colspan="1">RT: 490 pts; No RT: 638 pts</td><td align="left" valign="top" rowspan="1" colspan="1">5y: whole study population: 37%</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">5y: RT:90%, No RT: 80%, P<0.001</td><td align="left" valign="top" rowspan="1" colspan="1">Adjuvant RT</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Zwahlen 2013</td><td align="left" valign="top" rowspan="1" colspan="1">1987-2007, 124</td><td align="left" valign="top" rowspan="1" colspan="1">66.5</td><td align="left" valign="top" rowspan="1" colspan="1">I:52%, II:14%, III: 28%, IV: 3%</td><td align="left" valign="top" rowspan="1" colspan="1">9.7%</td><td align="left" valign="top" rowspan="1" colspan="1">40</td><td align="left" valign="top" rowspan="1" colspan="1">61%</td><td align="left" valign="top" rowspan="1" colspan="1">RT: 88%, ChT: 20%</td><td align="left" valign="top" rowspan="1" colspan="1">5y: 51.7%</td><td align="left" valign="top" rowspan="1" colspan="1">5y: 53.7.6%</td><td align="left" valign="top" rowspan="1" colspan="1">5y: 58.6%</td><td align="left" valign="top" rowspan="1" colspan="1">5y: 48%</td><td align="left" valign="top" rowspan="1" colspan="1">adjuvant RT, FIGO stage I-II vs. III-IV, age (60 vs. > 60 years). LAD, higher BT dose</td></tr></tbody></table><table-wrap-foot><fn><p>FIGO, International Federation of Gyneecology and Obstetrics; FU, follow up; LAD, lymphadenectomy; OS, overall survival; DFS, disease free survival; CSS, cause-specific survival; LRC, locoregional control; NR, not reported; ChT, Chemotherapy; HT, hormonal therapy; RT, radiotherapy; EBRT, External Beam RT; BT, Brachytherapy; Tx, Treatment; MT, metastases; Sx, surgery; BSO, bilateral salpingooophorectomy; pts, patients, n.s., not statistically significant; Numbers underlined represent UCS only; Other abbreviations as in <xref ref-type="table" rid="table001">Tables 1</xref> and <xref ref-type="table" rid="table002">2</xref>.</p></fn></table-wrap-foot></table-wrap></floats-group></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000634 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000634 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Curation
|type= RBID
|clé= PMC:4935818
|texte= Outcome and Predictive Factors in Uterine Carcinosarcoma Using Postoperative Radiotherapy: A Rare Cancer Network Study
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:27441069" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |